H.R. 999: Right to Contraception Act
This bill, titled the Right to Contraception Act, aims to establish and protect the right to access contraception for individuals and the right of health care providers to offer contraceptives and related services. The primary objectives and provisions of the bill include:
Definitions
- Contraception: Actions taken to prevent pregnancy, including both contraceptives and sterilization procedures.
- Contraceptive: Any drug, device, or product intended to prevent pregnancy.
- Health care provider: Individuals or entities licensed to provide health care services, including doctors, nurses, and pharmacists.
Key Findings
The bill asserts several findings regarding contraception, including:
- Access to contraception is a fundamental right linked to privacy, health, and individual dignity.
- Significant court rulings (e.g., Griswold v. Connecticut) support the constitutional right to contraception.
- Contraception is recognized internationally as a human right that enhances health and equality.
- Many marginalized groups face barriers to accessing contraception due to socio-economic inequities.
Purposes of the Act
The purposes of this Act are to:
- Establish a clear right to access contraceptives.
- Allow individuals to obtain contraception and engage in family planning.
- Protect individual choices regarding their bodies and health care.
Permitted Services
Individuals have the right to:
- Obtain contraceptives and engage in contraception without coercion.
- Receive guidance and services related to contraception from health care providers.
Limitations on Access
The Act restricts any limitations on access to contraceptives that:
- Specifically single out contraception or contraceptive providers.
- Impedes access to contraceptives or related information.
Applicability
This Act would apply to state and federal laws, superseding existing laws that restrict contraceptive access. However, it will not affect laws related to health insurance coverage requirements.
Enforcement Mechanisms
- The Attorney General can initiate legal action against states or officials that violate the Act.
- Individuals may also sue if they are adversely affected by violations, with provisions for equitable relief and coverage for legal costs.
Severability Clause
If any part of the Act is found unconstitutional, the remaining provisions will still stand.
Relevant Companies
- PFE (Pfizer Inc.): As a pharmaceutical company that produces contraceptive products, Pfizer may be affected by any changes in regulations or access issues related to contraceptives.
- MRK (Merck & Co., Inc.): Involved in producing contraceptive options, changes in accessibility defined by this Act could influence their business operations.
- TEVA (Teva Pharmaceutical Industries Limited): This company produces generic contraceptive products and could see a direct impact on sales and distribution should this Act change the market landscape for contraceptives.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
205 bill sponsors
-
Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
Actions
2 actions
Date | Action |
---|---|
Feb. 05, 2025 | Introduced in House |
Feb. 05, 2025 | Referred to the House Committee on Energy and Commerce. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.